首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-Å structure of the heparin-bridged complex
【2h】

Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-Å structure of the heparin-bridged complex

机译:肝素桥接复合物的1.6-Å结构揭示了蛋白C抑制剂识别凝血酶的分子基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Protein C inhibitor (PCI) is a serpin with many roles in biology, including a dual role as pro- and anticoagulant in blood. The protease specificity and local function of PCI depend on its interaction with cofactors such as heparin-like glycosaminoglycans (GAGs) and thrombomodulin (TM). Both cofactors significantly increase the rate of thrombin inhibition, but GAGs serve to promote the anticoagulant activity of PCI, and TM promotes its procoagulant function. To gain insight into how PCI recognition of thrombin is aided by these cofactors, we determined a crystallographic structure of the Michaelis complex of PCI, thrombin, and heparin to 1.6 Å resolution. Thrombin interacts with PCI in an unusual fashion that depends on the length of PCI's reactive center loop (RCL) to align the heparin-binding sites of the two proteins. The principal exosite contact is engendered by movement of thrombin's 60-loop in response to the unique P2 Phe of PCI. This mechanism of communication between the active site of thrombin and its recognition exosite is previously uncharacterized and may relate to other thrombin substrate–cofactor interactions. The cofactor activity of heparin thus depends on the formation of a heparin-bridged Michaelis complex and substrate-induced exosite contacts. We also investigated the cofactor effect of TM, establishing that TM bridges PCI to thrombin through additional direct interactions. A model of the PCI–thrombin–TM complex was built and evaluated by mutagenesis and suggests distinct binding sites for heparin and TM on PCI. These data significantly improve our understanding of the cofactor-dependent roles of PCI in hemostasis.
机译:蛋白C抑制剂(PCI)是丝氨酸蛋白酶抑制剂,在生物学中具有许多作用,包括在血液中作为促凝剂和抗凝剂双重作用。 PCI的蛋白酶特异性和局部功能取决于其与辅因子如肝素样糖胺聚糖(GAGs)和血栓调节蛋白(TM)的相互作用。两种辅因子均显着提高了凝血酶抑制率,但是GAG起到促进PCI抗凝活性的作用,而TM则促进其促凝功能。为了深入了解凝血酶对PCI的识别如何通过这些辅助因子来辅助,我们确定了PCI,凝血酶和肝素的Michaelis复合物的晶体结构,分辨率为1.6。凝血酶以与众不同的方式与PCI相互作用,这取决于PCI的反应性中心环(RCL)的长度,以对齐两种蛋白质的肝素结合位点。主要的异位接触是由于凝血酶的60环运动响应PCI独特的P2 Phe而引起的。凝血酶的活性位点与其识别异位点之间的这种通讯机制以前尚不明确,可能与其他凝血酶底物-辅因子相互作用有关。肝素的辅因子活性因此取决于肝素桥接的米氏菌复合物的形成和底物诱导的异位接触。我们还研究了TM的辅因子效应,确定TM通过其他直接相互作用将PCI与凝血酶桥接。通过诱变建立并评估了PCI-凝血酶-TM复合物模型,并提出了肝素和TM在PCI上的独特结合位点。这些数据极大地提高了我们对PCI在止血中依赖辅因子的作用的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号